STAASTAAR SURGICAL CO
Ophthalmic Goods
- Revenue
- $239M
- 24% YoY
- Operating margin
- -38.3%
- 853% YoY
- EBITDA
- −$83M
- 1358% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired13% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-19% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2026 | YoY |
|---|---|---|---|---|---|
| Revenue | $239M | $322M | $314M | $239M | 24% |
| Operating income | $44M | $28M | −$13M | −$92M | 627% |
| Net income | $40M | $21M | −$20M | −$80M | 298% |
| Operating cash flow | $36M | $15M | $16M | −$34M | 318% |
| Capex | $18M | $18M | $23M | $6M | 75% |
| Stock-based comp | $20M | $24M | $27M | $31M | 12% |
| Buybacks | — | — | — | $6M |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2026 | — | — | 30 | 100 |
| FY2024 | — | — | 31 | 95 |
| FY2023 | — | — | 39 | 89 |
| FY2022 | — | — | 61 | 89 |
| FY2021 | — | — | 115 | 111 |